- Home
- IMCC vs BCDA Comparison
IMCC vs BCDA Comparison
Compare IMCC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- BCDA
- Stock Information
- Founded
- IMCC 1980
- BCDA N/A
- Country
- IMCC Israel
- BCDA United States
- Employees
- IMCC N/A
- BCDA N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- BCDA Health Care
- Exchange
- IMCC Nasdaq
- BCDA Nasdaq
- Market Cap
- IMCC 5.0M
- BCDA 7.9M
- IPO Year
- IMCC N/A
- BCDA N/A
- Fundamental
- Price
- IMCC $2.23
- BCDA $2.60
- Analyst Decision
- IMCC
- BCDA Strong Buy
- Analyst Count
- IMCC 0
- BCDA 1
- Target Price
- IMCC N/A
- BCDA $25.00
- AVG Volume (30 Days)
- IMCC 11.8K
- BCDA 74.1K
- Earning Date
- IMCC 11-11-2024
- BCDA 11-06-2024
- Dividend Yield
- IMCC N/A
- BCDA N/A
- EPS Growth
- IMCC N/A
- BCDA N/A
- EPS
- IMCC N/A
- BCDA N/A
- Revenue
- IMCC $36,445,402.00
- BCDA $428,000.00
- Revenue This Year
- IMCC $22.59
- BCDA $6.92
- Revenue Next Year
- IMCC $20.53
- BCDA N/A
- P/E Ratio
- IMCC N/A
- BCDA N/A
- Revenue Growth
- IMCC N/A
- BCDA 0.71
- 52 Week Low
- IMCC $1.13
- BCDA $1.96
- 52 Week High
- IMCC $8.10
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- IMCC 41.06
- BCDA 46.60
- Support Level
- IMCC $2.02
- BCDA $2.39
- Resistance Level
- IMCC $2.15
- BCDA $2.84
- Average True Range (ATR)
- IMCC 0.14
- BCDA 0.17
- MACD
- IMCC -0.01
- BCDA -0.00
- Stochastic Oscillator
- IMCC 19.15
- BCDA 41.18
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).